Tarbox Family Office Inc. held its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,071 shares of the life sciences company’s stock at the end of the second quarter. Tarbox Family Office Inc.’s holdings in Illumina were worth $186,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in ILMN. Jennison Associates LLC raised its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock worth $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares during the last quarter. Baird Financial Group Inc. raised its stake in shares of Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock valued at $47,629,000 after buying an additional 256,061 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock valued at $65,577,000 after buying an additional 145,231 shares during the last quarter. 93.81% of the stock is currently owned by institutional investors.
Illumina, Inc. (NASDAQ:ILMN) traded down 0.21% on Friday, reaching $194.25. The company’s stock had a trading volume of 695,985 shares. The firm has a 50-day moving average of $179.63 and a 200 day moving average of $173.73. The company has a market capitalization of $28.36 billion, a price-to-earnings ratio of 38.97 and a beta of 0.83. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $199.95.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The company had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 earnings per share. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Tarbox Family Office Inc. Holds Position in Illumina, Inc. (NASDAQ:ILMN)” was originally reported by BNB Daily and is owned by of BNB Daily. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/14/tarbox-family-office-inc-continues-to-hold-stake-in-illumina-inc-nasdaqilmn-updated-updated-updated.html.
Several research analysts have recently weighed in on ILMN shares. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective on the stock in a research note on Monday, April 24th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. J P Morgan Chase & Co restated an “overweight” rating and issued a $250.00 target price on shares of Illumina in a research report on Wednesday, August 2nd. BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $175.00 price target (up from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $177.01.
In other news, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the transaction, the senior vice president now owns 10,791 shares in the company, valued at approximately $1,993,637.25. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total value of $1,950,000.00. Following the completion of the sale, the senior vice president now directly owns 76,585 shares of the company’s stock, valued at $14,934,075. The disclosure for this sale can be found here. Insiders have sold 134,010 shares of company stock worth $23,946,015 in the last three months. 1.60% of the stock is currently owned by corporate insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.